Opinion: Mother Nature is not ‘the ultimate bioterrorist’
Despite the menacing track record of emerging pathogens, “Mother Nature is the world’s worst bioterrorist,”…
Category: biotechnology
Opinion: Even in a virtual JPM week, we need to maintain the relationship glue that keeps the biotech industry strong
Every January, the week of the annual J.P. Morgan Healthcare Conference (JPM week) is a…
STAT+: Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
Sarepta Therapeutics on Thursday announced mixed results from the first randomized clinical trial of its…
STAT+: With success in vaccines, scientists try to turn mRNA against autoimmune diseases
The technology used in a pair of pioneering Covid-19 vaccines works by effectively revving up…
STAT+: With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
Just over two months after announcing its debut with $108 million in funding, Boston startup…
Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
John Hood is at it again. In 2016, Hood started a company, Impact BioMedicines, around…
STAT+: Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors
Almost five years after debuting his first biotech company, noted writer and oncologist Siddhartha Mukherjee…
STAT+: Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?
In a typical year, a biotech startup might hope to raise enough money to keep…
STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first…
STAT+: The biotech 2021 preview, from M&A to gene therapy and more
Hello, Biotech 2021. In the interest of humility, we’ll note that last year’s preview story…
STAT+: 3 biotech trends to watch
For biotech companies, 2020 could have been a lot worse than it was, all things…
Opinion: STAT+: ‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well
With the Moderna vaccine, Massachusetts is having a moment. Ours is a story not about…
STAT+: How 2020 became the year of the biotech SPAC
Over the past year, the humble blank-check IPO has risen from a disreputable relic of…
STAT+: The most impressive biotech VCs of 2020
Behind almost every biotech IPO, every merger, and every buyout are a set of venture…
STAT+: Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient
UniQure, the Dutch gene therapy company, said Monday that it had temporarily halted the clinical…
STAT+: Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases
Agios Pharmaceuticals said Monday that it is selling its cancer business to the French drug…
Listen: Moderna’s vaccine milestone, Warp Speed’s hurdles, and biotech in 2021
How long do Covid-19 vaccines last? Who should get them first? And when will we…
STAT+: Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list
The best and worst biopharma CEOs of 2020, selected by STAT+ readers, are Sam Kulkarni…
STAT+: Biogen to pay $22 million for illegally using charities to pay kickbacks to Medicare patients
Biogen (BIIG) has agreed to pay $22 million to resolve allegations that donations it paid…
Virtual Event: A look ahead at biotech in 2021
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. …
STAT+: Sage Therapeutics names former Alnylam exec Barry Greene as its new CEO
Sage Therapeutics is making a significant leadership change, hiring Barry Greene, the recently departed president…
STAT+: Here are the nominees for worst biopharma CEO of 2020
I told my editor that writing the worst CEOs of biopharma column is one of…
STAT+: Here are the nominees for best biopharma CEO of 2020
A year like no other requires a new way of drafting a list of Best…
STAT+: A new biotech tries to bridge the drug innovation gap between East and West
A growing number of Chinese biotech companies are trying to bridge the drug innovation gap…
STAT+: AstraZeneca to acquire Alexion for $39 billion, adding blockbuster immune medicines
AstraZeneca on Saturday said it was acquiring Alexion Pharmaceuticals for $39 billion, marking a significant…
STAT+: New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases
A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining…
‘I just white-knuckle it’: Hemophilia patients pin their hopes on the revival of Vioxx to fill a void in pain relief
After surviving hemophilia, hepatitis C, and HIV, Joseph Burke considers himself a walking miracle. But…
STAT+: Months of limbo at OpenBiome put fecal matter transplants on hold across the country
New regulations put in place because of Covid-19 have left one of the largest U.S….
STAT+: Divergent results from Agios, Forma trials for their sickle cell disease drugs
Two drug makers — Forma Therapeutics and Agios Pharmaceuticals — are each developing their own…
STAT+: With new data and a storied history, Eli Lilly’s blood cancer pill is looking stronger
Three years ago, the biotech firm Loxo Oncology purchased a promising blood cancer pill for…
STAT+: Constellation’s blood cancer drug shows greater benefit, easing concerns about its future
More patients and an improved response rate might once again shift the sentiment on Constellation…
STAT+: J&J’s CAR-T drug maintains strong efficacy in myeloma, shaded by neurotoxicity
More than three-quarters of the multiple myeloma patients treated with an experimental CAR-T therapy from…
STAT+: Genetically targeted drug from Kura Oncology induces remissions in adult leukemia patients
Kura Oncology presented early clinical trial results Saturday showing for the first time that its…
Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible
Ten patients treated with a CRISPR-based gene-editing therapy for the inherited blood disorders sickle cell…
STAT+: A longtime health care investor on the wild ride of 2020 and what to expect in 2021
It’s time to talk about biotech and 2021. What will the year ahead look like…
AstraZeneca’s confusing vaccine data, biotech in 2021, and a guide to the ASH conference
Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And…
STAT+: Agios drug for rare form of anemia achieves main goal of late-stage clinical trial
Agios Pharmaceuticals said Tuesday that its experimental drug mitapivat increased hemoglobin levels in patients with…
STAT+: Legend Biotech believes it is not a target of Chinese investigation, CEO says
The new CEO of Legend Biotech says the company has seen no indication that it…
STAT+: Startup Spotlight: Bullish on its asthma treatment, Kinaset forges ahead in unusual times
Launching a clinical trial for a drug intended to treat severe asthma during a respiratory…
Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy
Moderna said Monday that its Covid-19 vaccine continued to deliver strong efficacy results, showing 94%…
.jpg)
STAT+: In major bet, Biogen pays $1.5 billion for rights to a once-failed treatment for depression
Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the…
STAT+: Alnylam wins FDA approval for first drug to treat rare kidney disease
Alnylam Pharmaceuticals Inc. scored its third approval from the US Food and Drug Administration in…
STAT+: A new startup wants to use natural killer cells to fight cancer
On a blustery day last December, five biotech entrepreneurs and scientists walked past the snow-draped…
STAT+: Merck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge
The drug giant Merck said Monday it would purchase Rockville, Md.-based OncoImmune for $425 million…
STAT+: Raging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing
In March, as waves of Covid-19 cases began surging across the U.S., biotech venture capitalist…
STAT+: Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval
Brainstorm Cell Therapeutics reported disappointing results Tuesday from a late-stage clinical trial involving its experimental…
STAT Plus: STAT+ Conversations: How Covid-19 will change drug development
Editor’s note: A live stream of the conversation will be embedded below at 1 p.m….
STAT Plus: ‘The largest application we can imagine’: Illumina and Grail CEOs defend their deal to investors
Shares of Illumina, the leader in DNA sequencing, have dropped 13% since news leaked last…
STAT Plus: A sadly familiar disappointment in Alzheimer’s research
After years of failed attempts to treat Alzheimer’s disease by targeting a toxic brain plaque…
STAT Virtual Event: The ESMO Recap, Live!
Editor’s note: A live stream of the event will be embedded above at 1:30 p.m….